Harton Therapeutics Unveils Automated Cell Therapy Platform
Harton Therapeutics has unveiled a GMP-compliant, benchtop instrument for automated cell therapy manufacturing. The platform is designed to produce infusion-ready therapies from leukopak or whole blood and features digital batch records and real-time quality assurance. The system represents a move toward modular, integrated solutions that can scale from clinical development to commercial production.
- The global cell and gene therapy manufacturing market was valued at USD 7.28 billion in 2022 and is projected to reach USD 47.1 billion by 2030, with a compound annual growth rate of 26.3%. This growth highlights the urgent need for scalable manufacturing solutions to overcome production bottlenecks that delay clinical trials and commercial launches. - Harton's core technology, the Solid-State Bioprocessor (SSB), utilizes a structured 3D microenvironment that aims to replicate the physical and biochemical cues cells experience *in vivo*. This approach contrasts with traditional 2D flasks or suspension bioreactors, which can alter cell identity and function. - The HT-1 platform integrates real-time sensor data with configurable, automated workflows, allowing for adaptive process control that can respond to biological variations between different donors or cell lines. This addresses a key challenge in cell therapy, where the variability of starting materials is a significant concern for product consistency. - Founded in 2021 by CEO and CTO Richard Terry, the Cambridge, MA-based company has received investment from Decheng Capital and The Engine, an incubator and accelerator for "Tough Tech". The founders are scheduled to attend the 44th J.P. Morgan Healthcare Conference in January 2026. - A critical component of GMP-compliant systems is the electronic batch record (eBR), which replaces paper-based records that risk transcription errors and data loss. The Harton system's software is designed to capture every run as structured digital data to support traceability and compliance, a key feature for platforms seeking to meet FDA 21 CFR Part 11 requirements. - The industry-wide shift towards automation is a direct response to the high cost and complexity of manual processes, which are considered a primary driver of high therapeutic costs and a barrier to patient access. Competitors in the automated, closed-system space include Miltenyi Biotec's CliniMACS Prodigy and Terumo BCT's Quantum Cell Expansion System. - Contract Development and Manufacturing Organizations (CDMOs) represent a major segment of the market, holding over 66% of the revenue share in 2022 as therapy developers increasingly outsource manufacturing to leverage external expertise and capacity.
